Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? (2025)

Peer-Reviewed Study · Patel Y; Chawla J; Parmar MS · September 2025

Patel Y et al., 2025-09: 2025 review that accepts the preclinical anticancer signal (Wnt/beta-catenin, Akt/mTOR, apoptosis) but states there is no large-scale randomised trial evidence in humans and warns about self-medication toxicity in oncology patients.

Preclinical studies (in vitro and animal studies) demonstrate Ivermectin's anticancer effects, including inhibition of cancer cell proliferation, induction of apoptosis, and modulation of signaling pathways (e.g., Wnt/β-catenin, Akt/mTOR) across various cancers. However, clinical evidence in humans is limited, with no large-scale randomized controlled trials (RCTs) confirming therapeutic benefits.

n/a (PubMed abstract)

Patel Y et al., 2025-09: 2025 review that accepts the preclinical anticancer signal (Wnt/beta-catenin, Akt/mTOR, apoptosis) but states there is no large-scale randomised trial evidence in humans and warns about self-medication toxicity in oncology patients. Study type: narrative review. N: not stated. Country: USA (Nova Southeastern University, Clearwater FL). Dose/route/schedule: n/a. Declared COI: 'The authors declare no competing interests.' The paper also discloses use of GenAI for grammar editing of the draft. Comparator: n/a. Excerpt is two consecutive sentences from the abstract. Also filed as IVD-37 (claims C1, C6). Study type: review.